nodes	percent_of_prediction	percent_of_DWPC	metapath
Tizanidine—ADRA2C—attention deficit hyperactivity disorder	0.611	0.701	CbGaD
Tizanidine—ADRA2A—attention deficit hyperactivity disorder	0.261	0.299	CbGaD
Tizanidine—Brimonidine—ADRA2C—attention deficit hyperactivity disorder	0.0025	0.3	CrCbGaD
Tizanidine—Apraclonidine—ADRA2C—attention deficit hyperactivity disorder	0.00223	0.267	CrCbGaD
Tizanidine—Clonidine—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.134	CrCbGaD
Tizanidine—Brimonidine—ADRA2A—attention deficit hyperactivity disorder	0.00107	0.128	CrCbGaD
Tizanidine—Apraclonidine—ADRA2A—attention deficit hyperactivity disorder	0.000949	0.114	CrCbGaD
Tizanidine—Clonidine—ADRA2A—attention deficit hyperactivity disorder	0.000476	0.0571	CrCbGaD
Tizanidine—ADRA2C—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000226	0.00188	CbGpPWpGaD
Tizanidine—ADRA2A—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.000216	0.00179	CbGpPWpGaD
Tizanidine—ADRA2A—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.000214	0.00178	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000213	0.00177	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000209	0.00174	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000204	0.00169	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000195	0.00162	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000189	0.00157	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000185	0.00154	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000184	0.00153	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000182	0.00151	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00017	0.00141	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000169	0.0014	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000162	0.00135	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000162	0.00134	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000159	0.00132	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000159	0.00132	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000159	0.00132	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000158	0.00131	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000149	0.00124	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000149	0.00123	CbGpPWpGaD
Tizanidine—ADRA2B—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.000148	0.00123	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000148	0.00123	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000145	0.00121	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000145	0.0012	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000143	0.00119	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000141	0.00117	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000139	0.00116	CbGpPWpGaD
Tizanidine—ADRA2C—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.000138	0.00115	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000138	0.00115	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000138	0.00115	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000137	0.00114	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000137	0.00114	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000135	0.00112	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000134	0.00111	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000133	0.0011	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000132	0.00109	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000131	0.00109	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00013	0.00108	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00013	0.00108	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000129	0.00107	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000128	0.00107	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000128	0.00107	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000128	0.00106	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000127	0.00105	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000124	0.00103	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000124	0.00103	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000123	0.00102	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.00101	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000121	0.00101	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000121	0.001	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000121	0.001	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000121	0.001	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00012	0.000999	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000118	0.000982	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000118	0.000977	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000116	0.000964	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000114	0.000947	CbGpPWpGaD
Tizanidine—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000113	0.000936	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000112	0.000933	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000112	0.000931	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000112	0.00093	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000111	0.000919	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00011	0.000916	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00011	0.000915	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00011	0.000913	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00011	0.000913	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000109	0.000903	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000106	0.000884	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000106	0.000877	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000105	0.000869	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000104	0.000865	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000104	0.000862	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000103	0.000858	CbGpPWpGaD
Tizanidine—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000103	0.000856	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000103	0.000856	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000103	0.000856	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000101	0.000838	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	9.84e-05	0.000817	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	9.8e-05	0.000814	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.64e-05	0.000801	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	9.63e-05	0.0008	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	9.6e-05	0.000798	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	9.43e-05	0.000783	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	9.18e-05	0.000762	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	9.13e-05	0.000758	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9e-05	0.000748	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.99e-05	0.000747	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.96e-05	0.000744	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	8.93e-05	0.000742	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.68e-05	0.000721	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	8.65e-05	0.000718	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.53e-05	0.000708	CbGpPWpGaD
Tizanidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.43e-05	0.0007	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.43e-05	0.0007	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.4e-05	0.000697	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	8.39e-05	0.000697	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.37e-05	0.000695	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	8.37e-05	0.000695	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	8.33e-05	0.000692	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.17e-05	0.000678	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.11e-05	0.000673	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.97e-05	0.000662	CbGpPWpGaD
Tizanidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.87e-05	0.000654	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.87e-05	0.000654	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.85e-05	0.000652	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	7.82e-05	0.000649	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	7.63e-05	0.000634	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.63e-05	0.000633	CbGpPWpGaD
Tizanidine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	7.43e-05	0.000617	CbGpPWpGaD
Tizanidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	7.43e-05	0.000617	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.34e-05	0.00061	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.33e-05	0.000609	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	7.31e-05	0.000607	CbGpPWpGaD
Tizanidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.22e-05	0.0006	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	7.13e-05	0.000592	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	6.96e-05	0.000578	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.86e-05	0.000569	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	6.82e-05	0.000567	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	6.8e-05	0.000565	CbGpPWpGaD
Tizanidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.74e-05	0.00056	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.59e-05	0.000547	CbGpPWpGaD
Tizanidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.39e-05	0.000531	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.39e-05	0.000531	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.32e-05	0.000525	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.23e-05	0.000518	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.2e-05	0.000514	CbGpPWpGaD
Tizanidine—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.03e-05	0.000501	CbGpPWpGaD
Tizanidine—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.99e-05	0.000497	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.96e-05	0.000495	CbGpPWpGaD
Tizanidine—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.95e-05	0.000494	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.82e-05	0.000483	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.73e-05	0.000476	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.66e-05	0.00047	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.57e-05	0.000463	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.5e-05	0.000457	CbGpPWpGaD
Tizanidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.48e-05	0.000455	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.45e-05	0.000452	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.35e-05	0.000445	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.29e-05	0.000439	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.14e-05	0.000426	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.09e-05	0.000423	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.06e-05	0.000421	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.95e-05	0.000411	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.92e-05	0.000409	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.9e-05	0.000407	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.82e-05	0.000401	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.82e-05	0.0004	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.76e-05	0.000395	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.73e-05	0.000393	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.73e-05	0.000393	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.73e-05	0.000393	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.62e-05	0.000384	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.6e-05	0.000382	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.58e-05	0.00038	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.51e-05	0.000374	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.5e-05	0.000374	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.47e-05	0.000371	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.45e-05	0.00037	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.45e-05	0.000369	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.44e-05	0.000368	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.42e-05	0.000367	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.38e-05	0.000364	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.35e-05	0.000361	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.32e-05	0.000359	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.3e-05	0.000357	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.29e-05	0.000357	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.17e-05	0.000346	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.16e-05	0.000346	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.14e-05	0.000344	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.13e-05	0.000343	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.09e-05	0.00034	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.04e-05	0.000335	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.03e-05	0.000335	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.84e-05	0.000319	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.8e-05	0.000315	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	3.8e-05	0.000315	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.76e-05	0.000312	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.75e-05	0.000312	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.74e-05	0.00031	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	3.73e-05	0.00031	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.72e-05	0.000309	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.66e-05	0.000304	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.61e-05	0.0003	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.59e-05	0.000298	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.49e-05	0.00029	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.47e-05	0.000288	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.38e-05	0.000281	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.37e-05	0.000279	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.34e-05	0.000278	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.28e-05	0.000272	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.12e-05	0.000259	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.11e-05	0.000258	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	3.08e-05	0.000256	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.08e-05	0.000256	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.06e-05	0.000254	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.03e-05	0.000252	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	3.03e-05	0.000252	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.92e-05	0.000243	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.9e-05	0.000241	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.89e-05	0.00024	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.82e-05	0.000234	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.82e-05	0.000234	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.73e-05	0.000227	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.72e-05	0.000226	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.64e-05	0.000219	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.63e-05	0.000219	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	2.6e-05	0.000216	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.59e-05	0.000215	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.55e-05	0.000212	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.54e-05	0.000211	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.54e-05	0.000211	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.47e-05	0.000205	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.47e-05	0.000205	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.46e-05	0.000204	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	2.43e-05	0.000202	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.42e-05	0.000201	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.39e-05	0.000198	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.38e-05	0.000198	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.36e-05	0.000196	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	2.3e-05	0.000191	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	2.28e-05	0.00019	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.22e-05	0.000185	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.22e-05	0.000184	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.14e-05	0.000178	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.06e-05	0.000171	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2e-05	0.000166	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	1.98e-05	0.000164	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.94e-05	0.000161	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	1.87e-05	0.000155	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	1.86e-05	0.000154	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.81e-05	0.00015	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.7e-05	0.000141	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.7e-05	0.000141	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.67e-05	0.000139	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.67e-05	0.000138	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.56e-05	0.000129	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.56e-05	0.000129	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.36e-05	0.000113	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.3e-05	0.000108	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.26e-05	0.000105	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	1.03e-05	8.56e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	1.02e-05	8.5e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	9.93e-06	8.25e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	9.86e-06	8.19e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.83e-06	7.33e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.25e-06	6.85e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	8.01e-06	6.65e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.7e-06	5.56e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	4.42e-06	3.67e-05	CbGpPWpGaD
